RARE DISEASE
Necrotizing soft tissue infection
Necrotizing soft tissue infection
Necrotizing soft tissue infection
Synonyms: NSTI
Synonyms: NSTI
Synonyms: NSTI
Drug discovery
2
drugs
With orphan designations
Overview
Necrotizing soft tissue infection (NSTI) is a rapidly progressive, life-threatening bacterial or fungal infection causing tissue necrosis, systemic toxicity, and high mortality (6–76%) [1][4][7]. It primarily affects subcutaneous fat, fascia, or muscle, often arising from polymicrobial (70–80%) or monomicrobial (β-hemolytic streptococci, S. aureus) pathogens [1][3][10]. Diagnosis requires prompt surgical exploration due to nonspecific early symptoms (e.g., disproportionate pain, erythema) [6][16].
Categories: rare infectious diseases
Research Papers
1,001 drug discovery papers about Necrotizing soft tissue infection, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,001 drug discovery papers about Necrotizing soft tissue infection, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-09 | Conservative Management of Invasive Group A Streptococcal Infection With Cervical Necrotizing Fasciitis-Spectrum Disease and Pneumonia in a Healthy Young Adult.
Invasive Group A streptococcal (iGAS) infections are life-threatening conditions classically manifesting as necrotizing fasciitis or severe pneumonia, but their simultaneous occurrence in a previously healthy adult is extremely rare. While necrotizing fasciitis typically mandates urgent surgery, this report highlights a case of concurrent cervical necrotizing fasciitis-spectrum disease and pneumonia successfully managed through a conservative, non-surgical approach. A 29-year-old previously healthy Japanese male presented with a two-day history of fever, sore throat, and a maculopapular rash, with a throat swab positive for GAS. On Day 2, he acutely developed progressive dyspnea, hypoxemia, and extensive cervical subcutaneous emphysema. Computed tomography confirmed diffuse fascial edema and bilateral pulmonary infiltrates without signs of gas-forming abscess or irreversible tissue necrosis. Despite early amoxicillin administration, blood cultures remained negative, suggesting toxin-mediated clinical deterioration. Based on the imaging findings and close clinical monitoring, a non-operative strategy was selected. This was achieved by immediate medical escalation to broad-spectrum antimicrobials, including clindamycin to suppress toxin production, alongside meropenem and high-dose penicillin G. The patient recovered fully without surgical intervention. This case highlights that iGAS can cause rapid, concurrent soft-tissue and pulmonary involvement even in healthy individuals. In select cases of necrotizing fasciitis-spectrum disease where irreversible tissue necrosis is absent on prompt imaging and close clinical monitoring is maintained, aggressive multi-drug medical escalation incorporating antitoxin therapy can lead to successful outcomes without the need for morbid surgical procedures.
2026-07-29 | Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.
Vibrio vulnificus is a highly virulent pathogen associated with rapidly progressive sepsis and necrotising soft-tissue infection, particularly among patients with diabetes or chronic liver disease. Effective treatment options remain limited, especially in the setting of high bacterial burden or immunocompromis. We performed an integrated preclinical assessment of mitomycin C (MMC) alone and in combination with ciprofloxacin (CIP) using in vitro susceptibility testing and a neutropenic murine model challenged with increasing inocula of V. vulnificus. Myelotoxicity, organ-specific toxicity, and the development of resistance under subinhibitory MMC exposure were evaluated through haematological profiling and histopathology. MMC demonstrated potent in vitro activity and conferred complete protection in mice challenged with low bacterial inocula (103-104 colony-forming units (CFU)/mL). Although efficacy declined with increasing bacterial burden, combination therapy with MMC and ciprofloxacin significantly improved survival across all inoculum levels, achieving complete protection at concentrations up to 1.4 ⨯ 107 CFU/mL and partial protection at 4.3 ⨯ 107 CFU/mL. The combination regimen was not associated with dose-dependent myelosuppression, and no hepatotoxicity or nephrotoxicity was observed. Exposure to subinhibitory concentrations of MMC did not result in increased minimum inhibitory concentrations over time. MMC-CIP combination therapy demonstrated synergistic efficacy against severe V. vulnificus infection in a neutropenic mouse model and may represent a promising therapeutic option. Dose-limiting myelotoxicity and the potential for resistance necessitate cautious dosing and further clinical investigation. This study addresses a critical therapeutic gap in severe V. vulnificus infection by proposing a mechanistically rational, dose-optimized adjunctive strategy supported by robust preclinical evidence.
2026-07-17 | A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection.
Necrotizing soft tissue infections (NSTIs) caused by Streptococcus pyogenes (group A streptococcus [GAS]) are rapidly progressive, toxin-driven infections for which no targeted antitoxin therapies exist. Streptolysin O (SLO), a cholesterol-dependent cytolysin, is a key mediator of tissue injury, vascular occlusion, and immune dysfunction and, thus, represents a promising therapeutic target. Here, we isolated and characterized three fully human monoclonal antibodies (huMAbs) against SLO (C11, G4, and L17) from the memory B cells of a naturally immunized donor using antigen-specific B-cell enrichment. All three huMAbs bound SLO with high affinity and potently neutralized SLO-induced hemolysis in vitro. Mechanistic studies revealed that C11 and G4 inhibited SLO-membrane binding, whereas L17 protected host cells without blocking membrane binding. Despite similar neutralizing potency in vitro, only L17 significantly improved disease outcomes in vivo. In a murine model of GAS-NSTI, L17 reduced clinical disease severity and prolonged survival by approximately 130%. Together, these findings demonstrate that antibody-mediated neutralization of SLO can alter disease outcomes during GAS-necrotizing infection and support the potential of L17 as a clinically relevant antitoxin therapeutic candidate for GAS-NSTI.
2026-07-08 | Neorectal Perforation and Necrotizing Soft Tissue Infection of the Lower Limb Following Pelvic Reirradiation for Recurrent Rectal Cancer: A Case Report.
Neorectal perforation is a rare but serious complication following treatment for rectal cancer, and may lead to catastrophic sequelae if diagnosis and management are delayed. We report the case of a 54-year-old woman with locally recurrent rectal cancer who developed neorectal perforation and necrotizing soft tissue infection of the lower limb following chemoradiotherapy. Initial symptoms were attributed to sciatic nerve inflammation, and surgical consultation was delayed. The patient subsequently developed septic shock and was found to have extraperitoneal perforation extending through the greater sciatic foramen, with extensive necrotizing fasciitis of the gluteal and thigh compartments. Management required urgent laparotomy with resection of the colonic J pouch, omentoplasty, feeding gastrostomy, and extraperitoneal end colostomy, followed by multiple surgical debridements. The patient experienced prolonged critical illness, including multiorgan failure and colonization of wounds with multidrug-resistant organisms. Successful recovery was achieved through aggressive multidisciplinary care, including novel use of negative pressure wound therapy with acetic acid instillation. This case highlights the need for caution when re-irradiating the neorectum in the presence of a neorectal ulcer, and the importance of early surgical involvement in complex post-treatment complications.
2026-07-02 | Hemipelvectomy for Clostridium septicum necrotizing soft tissue infection with extensive pelvic organ destruction: a case report.
Clostridium septicum is a highly virulent, gas-forming, anaerobic Gram-positive bacillus known to cause rapidly progressive necrotizing soft tissue infection that is often associated with gastrointestinal malignancy or immunocompromised states. Mortality remains extremely high, with many patients dying within the first 24 h of onset. Although aggressive surgical debridement is the cornerstone of treatment, cases requiring hemipelvectomy are exceedingly rare, and postoperative management of exposed pelvic organs has not been described in the relevant literature. A 73-year-old woman with ascending colon cancer developed sudden severe left leg pain and paralysis, and computed tomography revealed extensive gas from the left thigh to the pelvis. Upon arrival at our tertiary center, she was in septic shock with gas rapidly progressing to the high retroperitoneum. Emergent hip disarticulation was performed, and Clostridium septicum was isolated. Despite early source control, ongoing toxin-mediated necrosis extending beyond the limits of limb amputation necessitated left hemipelvectomy on Day 4. Following radical debridement, postoperative management became extremely challenging because multiple pelvic organs were exposed, with necrosis of the bladder and perforation of ureter, rectum and vaginal wall. Serial debridement and staged repairs were required over a prolonged course. Granulation of the pelvic wound gradually progressed, allowing split-thickness skin grafting on Day 88, after which wound healing stabilized. She was ultimately stable enough to return to the referring hospital on Day 187. This is an extremely rare case of Clostridium septicum necrotizing soft tissue infection requiring hemipelvectomy, demonstrating that aggressive and timely radical debridement can be life-saving, even in cases with massive pelvic involvement. Furthermore, we present the first documented example of stepwise management of exposed pelvic organs after hemipelvectomy performed for necrotizing soft tissue infection, providing valuable insights for clinicians facing similar catastrophic presentations.
2026-08-09 | Conservative Management of Invasive Group A Streptococcal Infection With Cervical Necrotizing Fasciitis-Spectrum Disease and Pneumonia in a Healthy Young Adult.
Invasive Group A streptococcal (iGAS) infections are life-threatening conditions classically manifesting as necrotizing fasciitis or severe pneumonia, but their simultaneous occurrence in a previously healthy adult is extremely rare. While necrotizing fasciitis typically mandates urgent surgery, this report highlights a case of concurrent cervical necrotizing fasciitis-spectrum disease and pneumonia successfully managed through a conservative, non-surgical approach. A 29-year-old previously healthy Japanese male presented with a two-day history of fever, sore throat, and a maculopapular rash, with a throat swab positive for GAS. On Day 2, he acutely developed progressive dyspnea, hypoxemia, and extensive cervical subcutaneous emphysema. Computed tomography confirmed diffuse fascial edema and bilateral pulmonary infiltrates without signs of gas-forming abscess or irreversible tissue necrosis. Despite early amoxicillin administration, blood cultures remained negative, suggesting toxin-mediated clinical deterioration. Based on the imaging findings and close clinical monitoring, a non-operative strategy was selected. This was achieved by immediate medical escalation to broad-spectrum antimicrobials, including clindamycin to suppress toxin production, alongside meropenem and high-dose penicillin G. The patient recovered fully without surgical intervention. This case highlights that iGAS can cause rapid, concurrent soft-tissue and pulmonary involvement even in healthy individuals. In select cases of necrotizing fasciitis-spectrum disease where irreversible tissue necrosis is absent on prompt imaging and close clinical monitoring is maintained, aggressive multi-drug medical escalation incorporating antitoxin therapy can lead to successful outcomes without the need for morbid surgical procedures.
2026-07-29 | Synergistic activity of mitomycin C in combination with ciprofloxacin against severe Vibrio vulnificus infection.
Vibrio vulnificus is a highly virulent pathogen associated with rapidly progressive sepsis and necrotising soft-tissue infection, particularly among patients with diabetes or chronic liver disease. Effective treatment options remain limited, especially in the setting of high bacterial burden or immunocompromis. We performed an integrated preclinical assessment of mitomycin C (MMC) alone and in combination with ciprofloxacin (CIP) using in vitro susceptibility testing and a neutropenic murine model challenged with increasing inocula of V. vulnificus. Myelotoxicity, organ-specific toxicity, and the development of resistance under subinhibitory MMC exposure were evaluated through haematological profiling and histopathology. MMC demonstrated potent in vitro activity and conferred complete protection in mice challenged with low bacterial inocula (103-104 colony-forming units (CFU)/mL). Although efficacy declined with increasing bacterial burden, combination therapy with MMC and ciprofloxacin significantly improved survival across all inoculum levels, achieving complete protection at concentrations up to 1.4 ⨯ 107 CFU/mL and partial protection at 4.3 ⨯ 107 CFU/mL. The combination regimen was not associated with dose-dependent myelosuppression, and no hepatotoxicity or nephrotoxicity was observed. Exposure to subinhibitory concentrations of MMC did not result in increased minimum inhibitory concentrations over time. MMC-CIP combination therapy demonstrated synergistic efficacy against severe V. vulnificus infection in a neutropenic mouse model and may represent a promising therapeutic option. Dose-limiting myelotoxicity and the potential for resistance necessitate cautious dosing and further clinical investigation. This study addresses a critical therapeutic gap in severe V. vulnificus infection by proposing a mechanistically rational, dose-optimized adjunctive strategy supported by robust preclinical evidence.
2026-07-17 | A fully human streptolysin O-neutralizing monoclonal antibody improves survival in a murine model of group A streptococcus necrotizing soft tissue infection.
Necrotizing soft tissue infections (NSTIs) caused by Streptococcus pyogenes (group A streptococcus [GAS]) are rapidly progressive, toxin-driven infections for which no targeted antitoxin therapies exist. Streptolysin O (SLO), a cholesterol-dependent cytolysin, is a key mediator of tissue injury, vascular occlusion, and immune dysfunction and, thus, represents a promising therapeutic target. Here, we isolated and characterized three fully human monoclonal antibodies (huMAbs) against SLO (C11, G4, and L17) from the memory B cells of a naturally immunized donor using antigen-specific B-cell enrichment. All three huMAbs bound SLO with high affinity and potently neutralized SLO-induced hemolysis in vitro. Mechanistic studies revealed that C11 and G4 inhibited SLO-membrane binding, whereas L17 protected host cells without blocking membrane binding. Despite similar neutralizing potency in vitro, only L17 significantly improved disease outcomes in vivo. In a murine model of GAS-NSTI, L17 reduced clinical disease severity and prolonged survival by approximately 130%. Together, these findings demonstrate that antibody-mediated neutralization of SLO can alter disease outcomes during GAS-necrotizing infection and support the potential of L17 as a clinically relevant antitoxin therapeutic candidate for GAS-NSTI.
2026-07-08 | Neorectal Perforation and Necrotizing Soft Tissue Infection of the Lower Limb Following Pelvic Reirradiation for Recurrent Rectal Cancer: A Case Report.
Neorectal perforation is a rare but serious complication following treatment for rectal cancer, and may lead to catastrophic sequelae if diagnosis and management are delayed. We report the case of a 54-year-old woman with locally recurrent rectal cancer who developed neorectal perforation and necrotizing soft tissue infection of the lower limb following chemoradiotherapy. Initial symptoms were attributed to sciatic nerve inflammation, and surgical consultation was delayed. The patient subsequently developed septic shock and was found to have extraperitoneal perforation extending through the greater sciatic foramen, with extensive necrotizing fasciitis of the gluteal and thigh compartments. Management required urgent laparotomy with resection of the colonic J pouch, omentoplasty, feeding gastrostomy, and extraperitoneal end colostomy, followed by multiple surgical debridements. The patient experienced prolonged critical illness, including multiorgan failure and colonization of wounds with multidrug-resistant organisms. Successful recovery was achieved through aggressive multidisciplinary care, including novel use of negative pressure wound therapy with acetic acid instillation. This case highlights the need for caution when re-irradiating the neorectum in the presence of a neorectal ulcer, and the importance of early surgical involvement in complex post-treatment complications.
2026-07-02 | Hemipelvectomy for Clostridium septicum necrotizing soft tissue infection with extensive pelvic organ destruction: a case report.
Clostridium septicum is a highly virulent, gas-forming, anaerobic Gram-positive bacillus known to cause rapidly progressive necrotizing soft tissue infection that is often associated with gastrointestinal malignancy or immunocompromised states. Mortality remains extremely high, with many patients dying within the first 24 h of onset. Although aggressive surgical debridement is the cornerstone of treatment, cases requiring hemipelvectomy are exceedingly rare, and postoperative management of exposed pelvic organs has not been described in the relevant literature. A 73-year-old woman with ascending colon cancer developed sudden severe left leg pain and paralysis, and computed tomography revealed extensive gas from the left thigh to the pelvis. Upon arrival at our tertiary center, she was in septic shock with gas rapidly progressing to the high retroperitoneum. Emergent hip disarticulation was performed, and Clostridium septicum was isolated. Despite early source control, ongoing toxin-mediated necrosis extending beyond the limits of limb amputation necessitated left hemipelvectomy on Day 4. Following radical debridement, postoperative management became extremely challenging because multiple pelvic organs were exposed, with necrosis of the bladder and perforation of ureter, rectum and vaginal wall. Serial debridement and staged repairs were required over a prolonged course. Granulation of the pelvic wound gradually progressed, allowing split-thickness skin grafting on Day 88, after which wound healing stabilized. She was ultimately stable enough to return to the referring hospital on Day 187. This is an extremely rare case of Clostridium septicum necrotizing soft tissue infection requiring hemipelvectomy, demonstrating that aggressive and timely radical debridement can be life-saving, even in cases with massive pelvic involvement. Furthermore, we present the first documented example of stepwise management of exposed pelvic organs after hemipelvectomy performed for necrotizing soft tissue infection, providing valuable insights for clinicians facing similar catastrophic presentations.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Necrotizing soft tissue infection.
2 orphan drug designations for Necrotizing soft tissue infection.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH | peptides | EMA | 2014-07-29 | — | FGK Representative Service GmbH |
reltecimod | peptides | FDA | 2011-10-12 | — | Atox Bio, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.